Literature DB >> 2672819

A limited comparison of apraclonidine's dose response in subjects with normal or increased intraocular pressure.

D A Abrams1, A L Robin, A S Crandall, D R Caldwell, D B Schnitzer, I P Pollack, J E Rader, T A Reaves.   

Abstract

We performed a multicentered, placebo-controlled, randomized, crossover study comparing the efficacy of 0.5% and 1.0% apraclonidine hydrochloride in 15 normal volunteers and 17 subjects with increased intraocular pressure. Apraclonidine 1% produced a maximum 30.4% +/- 14.0% (4.7 +/- 2.4 mm Hg) decrease in mean intraocular pressure in normal eyes and a 31.3% +/- 16.5% (7.6 +/- 4.2 mm Hg) decrease in eyes with increased pressure. Apraclonidine 0.5% produced a maximum 25.8% +/- 9.7% (4.0 +/- 1.7 mm Hg) decrease in mean intraocular pressure in normal eyes and a 27.4% +/- 16.0% (6.8 +/- 4.5 mm Hg) decrease in eyes with increased pressure. There was no statistically significant difference in mean percent intraocular pressure lowering effect between the 0.5% and 1.0% apraclonidine concentrations. Most subjects treated with apraclonidine had a greater than or equal to 20% reduction in intraocular pressure from baseline. Twelve hours after instillation of apraclonidine, nine of the normal volunteers had an intraocular pressure of 10 mm Hg or less. Apraclonidine produced the same percent intraocular pressure decrease regardless of the initial level of intraocular pressure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2672819     DOI: 10.1016/0002-9394(89)90111-6

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

1.  Effectiveness of apraclonidine 1% in preventing intraocular pressure rise following macular hole surgery.

Authors:  A Sciscio; A G Casswell
Journal:  Br J Ophthalmol       Date:  2001-02       Impact factor: 4.638

2.  Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.

Authors:  A L Robin; R Ritch; D Shin; B Smythe; T Mundorf; R P Lehmann
Journal:  Trans Am Ophthalmol Soc       Date:  1995

Review 3.  New developments in the drug treatment of glaucoma.

Authors:  L M Hurvitz; P L Kaufman; A L Robin; R N Weinreb; K Crawford; B Shaw
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

4.  Effects of 0.5% apraclonidine on optic nerve head and peripapillary retinal blood flow.

Authors:  T W Kim; D M Kim
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

5.  Optic nerve vasomotor effects of topical apraclonidine hydrochloride.

Authors:  S Orgül; D R Bacon; E M Van Buskirk; G A Cioffi
Journal:  Br J Ophthalmol       Date:  1996-01       Impact factor: 4.638

6.  Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers.

Authors:  N Yüksel; C Güler; Y Caglar; O Elibol
Journal:  Int Ophthalmol       Date:  1992-09       Impact factor: 2.031

7.  Apraclonidine hydrochloride: an evaluation of plasma concentrations, and a comparison of its intraocular pressure lowering and cardiovascular effects to timolol maleate.

Authors:  A L Robin; A L Coleman
Journal:  Trans Am Ophthalmol Soc       Date:  1990

8.  Efficacy of apraclonidine ophthalmic solution (Iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma.

Authors:  E Gramer; S Busche; A Kampik; D Parsons
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-01       Impact factor: 3.117

9.  Intravenous administration of clonidine reduces intraocular pressure and alters ocular blood flow.

Authors:  Günther Weigert; Hemma Resch; Alexandra Luksch; Herbert A Reitsamer; Gabriele Fuchsjager-Mayrl; Leopold Schmetterer; Gerhard Garhofer
Journal:  Br J Ophthalmol       Date:  2007-05-30       Impact factor: 4.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.